Potential of β2-adrenoceptor agonists as add-on therapy for multiple sclerosis focus on salbutamol (albuterol)

CNS Drugs

Volumn 16, Issue 1, 2002, Pages 1-8

  Makhlouf, Karim ^a   Weiner, Howard L ^a   Khoury, Samia J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; SALBUTAMOL; TERBUTALINE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOLOGICAL ADJUVANT;

ADD ON THERAPY; AUTOIMMUNE DISEASE; BRONCHOSPASM; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREMOR; ANIMAL; DRUG COMBINATION; DRUG POTENTIATION;

ADJUVANTS, IMMUNOLOGIC; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0036008283     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216010-00001     Document Type: Review

References (40)

1. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans
2. Albuterol: An adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use
3. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol
4. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate
5. Axonal transection in the lesions of multiple sclerosis
6. Distribution of multiple sclerosis
7. Immunological mechanisms in multiple sclerosis
8. Revisiting the Th1/Th2 paradigm
9. Intefieukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
10. The role of IL-12 in the induction of organ-specific autoimmune diseases
11. Interferon beta in multiple sclerosis: Is IL-12 suppression the key?
12. Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
13. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
14. The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats
15. Experimental allergic encephalomyelitis, beta-adrenergic receptors and interferon gamma-secreting cells in beta-adrenergic agonist-treated rats
16. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats
17. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: Mechanisms of action
18. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production
19. Effect of albuterol and terbutaline, synthetic beta adrenergic stimulants, on the cyclic 3′,5′-adenosine monophosphate system in smooth muscle
20. Effect of adrenergic agents on alpha-amylase release and adenosine 3′,5′-monophosphate accumulation in rat parotid tissue slices
21. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12
22. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis
23. Increased expression of high affinity IL-2 receptors and beta- adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis
24. Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis
25. The CREB family of transcription activators
26. β-adrenergic agonists exert their 'anti-inflammatory' effects in monocytic cells through the IκB/NF-κB pathway
27. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B
28. Induction of interleukin-12/p40 by superantigens in macrophages is mediated by activation of nuclear factor-kappaB
29. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
30. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300
31. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism
32. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription
33. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL- 10 gene in monocytic cells
34. Regulation of interleukin-10 production by beta-adrenergic agonists
35. Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent
36. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
37. Prevention of autoimmune demyetination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
38. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors
39. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases